Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope

October 04, 2023 12:55 AM AEDT | By 3BL

Google News:

Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope — Image source: Kalkine Media

Recent News

Energy Surge Balances Weakness in Aussie Share Market on ASX 200

Santos Powers ASX 200 as Energy Stocks Boost the Aussie Share Market

Energy Stocks on the Move as Tensions Drive ASX 200 and All Ordinaries

U.S. households to keep buying stocks this year, Goldman Sachs says

Increasing diversity in clinical trials plays a crucial role in helping to understand how a broad range of human bodies may respond to treatments. That’s why our company joined Beacon of Hope, an initiative created by Novartis and the Novartis U.S. Foundation to create greater diversity, equity and inclusion across the research and development ecosystem.

Through this collaboration, we’re working to operate clinical trials through four Historically Black Medical School Clinical Trial Centers of Excellence established under Beacon of Hope. These schools are: Morehouse School of Medicine, Howard University College of Medicine, Meharry Medical College and Charles R. Drew University of Medicine and Science. The trials are conducted by investigators and trial managers of color and include participants from underrepresented communities.

“Merck is proud to participate in a collaboration focused on improving enrollment of underrepresented people in clinical trials with the common goal of ensuring these trials appropriately reflect the diversity of the patients we serve worldwide.”
Andy Lee
Head of global clinical trial operations, Merck

More about Beacon of Hope

Established in 2021, Beacon of Hope is an innovative collaboration with 26 Historically Black Colleges and Universities, and companies and organizations working together to address root causes of disparities in health and education. The initiative supports increasing diversity, equity and inclusion in clinical trials, new research into health care disparities, and breaking down barriers that often stand in the way of promising career opportunities for students of color.

Merck joined Beacon of Hope in 2022.

Our approach to increasing diversity in clinical trials

We take a multipronged approach in our efforts to conduct trials that include people from different backgrounds. It includes selecting trial sites with inclusion in mind, outreach and education tailored to communities, and ongoing learning from subject matter experts.

“A singular approach will not solve the challenge we face with the lack of diversity in U.S. clinical trials today — it has to be addressed from a higher level alongside our peers and colleagues and within the communities where potential participants live,” said Adrelia Allen, senior director of clinical trial patient diversity. “We know we can’t do this alone, and we must come together.”

“Diversity in our trials is not just an initiative — it’s our way of working. It’s woven into all steps of the trial process, and it must be proactive — not reactive.”
Adrelia Allen
Executive director of clinical trial patient diversity, Merck

View original content here.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.